Unknown

Dataset Information

0

Potential genetic predisposition for anthracycline-associated cardiomyopathy in families with dilated cardiomyopathy.


ABSTRACT: OBJECTIVE: Anthracyclines are successfully used in cancer treatment, but their use is limited by their cardiotoxic side effects. Several risk factors for anthracycline-associated cardiomyopathy (AACM) are known, yet the occurrence of AACM in the absence of these known risk factors suggests that other factors must play a role. The purpose of this study was to evaluate whether a genetic predisposition for dilated cardiomyopathy (DCM) could be a potential risk factor for AACM. METHODS: A hospital-based registry of 162 DCM families and two hospital-based registries of patients with cancer treated with systemic cancer therapy (n>6000) were reviewed focusing on AACM. Selected patients with AACM/DCM families with possible AACM (n=21) were analysed for mutations in cardiomyopathy-associated genes and presymptomatic cardiological evaluation of first-degree relatives was performed. RESULTS: We identified five DCM families with AACM and one patient with AACM with a family member with a possible early sign of mild DCM. Pathogenic MYH7 mutations were identified in two of these six families. The MYH7 c.1633G>A (p.Asp545Asn) and c.2863G>A (p.Asp955Asn) mutations (one double mutant allele) were identified in a DCM family with AACM. The MYH7 c.4125T>A (p.Tyr1375X) mutation was identified in one patient with AACM. CONCLUSIONS: This study further extends the hypothesis that a genetic predisposition to DCM could be a potential risk factor for AACM.

SUBMITTER: Wasielewski M 

PROVIDER: S-EPMC4195921 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature

altmetric image

Publications

Potential genetic predisposition for anthracycline-associated cardiomyopathy in families with dilated cardiomyopathy.

Wasielewski Marijke M   van Spaendonck-Zwarts Karin Y KY   Westerink Nico-Derk L ND   Jongbloed Jan D H JD   Postma Aleida A   Gietema Jourik A JA   van Tintelen J Peter JP   van den Berg Maarten P MP  

Open heart 20140718 1


<h4>Objective</h4>Anthracyclines are successfully used in cancer treatment, but their use is limited by their cardiotoxic side effects. Several risk factors for anthracycline-associated cardiomyopathy (AACM) are known, yet the occurrence of AACM in the absence of these known risk factors suggests that other factors must play a role. The purpose of this study was to evaluate whether a genetic predisposition for dilated cardiomyopathy (DCM) could be a potential risk factor for AACM.<h4>Methods</h4  ...[more]

Similar Datasets

| S-EPMC5528936 | biostudies-other
| S-EPMC4797319 | biostudies-literature
| S-EPMC5187458 | biostudies-other
| S-EPMC2955954 | biostudies-literature
| S-EPMC3399391 | biostudies-literature
| S-EPMC3533274 | biostudies-literature
| S-EPMC3516872 | biostudies-literature
| S-EPMC5449520 | biostudies-literature
| S-EPMC7004454 | biostudies-literature
| S-EPMC8079649 | biostudies-literature